T. Rowe Price Associates
RCEL icon

T. Rowe Price Associates’s Avita Medical RCEL Stock Holding History

T. Rowe Price Associates’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,869
Closed -$63K – 3105
2025
Q2 		$63K Buy
11,869
+248
+2% +$1.8K ﹤0.01% 2973
2025
Q1 		$95K Buy
11,621
+1,617
+16% +$15.1K ﹤0.01% 2828
2024
Q4 		$129K Sell
10,004
-9,796
-49% -$116K ﹤0.01% 2796
2024
Q3 		$213K Sell
19,800
-255
-1% -$2.4K ﹤0.01% 2632
2024
Q2 		$159K Buy
20,055
+5,596
+39% +$53.2K ﹤0.01% 2651
2024
Q1 		$232K Buy
14,459
+1,117
+8% +$18.1K ﹤0.01% 2547
2023
Q4 		$184K Buy
13,342
+200
+2% +$2.29K ﹤0.01% 2571
2023
Q3 		$193K Sell
13,142
-957
-7% -$16.2K ﹤0.01% 2515
2023
Q2 		$240K Buy
14,099
+3,499
+33% +$51.3K ﹤0.01% 2464
2023
Q1 		$149K Sell
10,600
-4,500
-30% -$47.9K ﹤0.01% 2595
2022
Q4 		$100K Hold
15,100
– – ﹤0.01% 2719
2022
Q3 		$80K Buy
+15,100
New +$93.2K ﹤0.01% 2773
2022
Q2 		– Sell
-11,290
Closed -$96K – 3004
2022
Q1 		$96K Buy
+11,290
New +$104K ﹤0.01% 2852

Other funds holding RCEL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

T. Rowe Price Associates's RCEL Position: Q3 2025 in Review

T. Rowe Price Associates sold out of Avita Medical (RCEL) in Q3 2025, closing a stake of 11,869 shares — an estimated $63K sold.

T. Rowe Price Associates first reported a position in RCEL in Q1 2022 and held it in 13 quarters. The position peaked at $240K in Q2 2023. 76 funds tracked by Wall St. Rank hold RCEL as of Q3 2025.

  • T. Rowe Price Associates reported no remaining Avita Medical position as of Q3 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 11,869 Avita Medical shares in Q3 2025, an estimated $63K.
  • T. Rowe Price Associates first reported a position in Avita Medical in Q1 2022 and held it in 13 quarters.
  • T. Rowe Price Associates's Avita Medical position peaked at $240K in Q2 2023.
  • 76 funds tracked by Wall St. Rank held Avita Medical as of Q3 2025.

Based on T. Rowe Price Associates's 13F filing for Q3 2025, filed 14 Nov 2025.